AC Immune has developed antibodies against two proteins that are key players in the neurodegeneration underlying Parkinson’s and other neurological diseases.
Articles by Patricia Inácio, PhD
AstraZeneca has partnered with Takeda Pharmaceutical to develop and commercialize the alpha-synuclein antibody MEDI1341 for…
The first treatment for levodopa-induced dyskinesia — the involuntary and jerky movements that afflict most Parkinson’s disease patients on this…
Virtual house calls with a neurologist can be as effective as in-person visits for Parkinson’s disease patients, offering convenience and…
The online Parkinson’s disease community GeneFo and Greg Macpherson, MitoQ‘s CEO, will conduct a free webinar on Aug. 24, at 1…
Researchers at the University of Pennsylvania developed a strategy using fluorescence that allows them to track alpha-synuclein protein and follow its…
Parkinson’s patients who injected themselves with the diabetes therapy Byetta (exenatide) every week for a year were able to move better,…
A Harvard University-designed soft robotic exosuit that helped stroke patients walk better could do the same for Parkinson’s and multiple…
Prexton Therapeutics has initiated a new Phase 2 clinical trial to assess the safety and effectiveness of its investigational therapy Foliglurax (PXT002331)…
International Stem Cell Corp. (ISCO) says two of its biggest achievements in the last quarter of 2016 was demonstrating that…